Late growth of infantile hemangiomas in children >3 years of age: A retrospective study.
Adrenal Cortex Hormones
/ therapeutic use
Age Factors
Child
Child, Preschool
Cohort Studies
Disease Progression
Female
Follow-Up Studies
Hemangioma, Capillary
/ congenital
Humans
Laser Therapy
/ methods
Male
Propranolol
/ therapeutic use
Retrospective Studies
Risk Assessment
Severity of Illness Index
Skin Neoplasms
/ congenital
Time Factors
Treatment Outcome
United States
corticosteroid
growth hormone
infantile hemangioma
late growth
segmental morphology
β-blocker
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
06
10
2017
revised:
16
07
2018
accepted:
23
07
2018
pubmed:
9
10
2018
medline:
7
3
2019
entrez:
9
10
2018
Statut:
ppublish
Résumé
The proliferative phase of infantile hemangiomas (IHs) is usually complete by 9 months of life. Late growth beyond age 3 years is rarely reported. To describe the demographic and clinic characteristics of a cohort of patients with late growth of IH, defined as growth in a patient >3 years of age. A multicenter, retrospective cohort study. In total, 59 patients, 85% of which were female, met the inclusion criteria. The mean first episode of late growth was 4.3 (range 3-8.5) years. Head and neck location (55/59; 93%) and presence of deep hemangioma (52/59; 88%) were common characteristics. Posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects, eye abnormalities (PHACE) syndrome was noted in 20 of 38 (53%) children with segmental facial IH. Systemic therapy (corticosteroid or β-blocker) was given during infancy in 58 of 59 (98%) and 24 of 59 (41%) received systemic therapy (β-blockers) for late IH growth. The retrospective nature and ascertainment by investigator recall are limitations of the study. Late IH growth can occur in children after 3 years of age. Risk factors include head and neck location, segmental morphology, and involvement of deep dermal/subcutaneous tissues.
Sections du résumé
BACKGROUND
BACKGROUND
The proliferative phase of infantile hemangiomas (IHs) is usually complete by 9 months of life. Late growth beyond age 3 years is rarely reported.
OBJECTIVE
OBJECTIVE
To describe the demographic and clinic characteristics of a cohort of patients with late growth of IH, defined as growth in a patient >3 years of age.
METHODS
METHODS
A multicenter, retrospective cohort study.
RESULTS
RESULTS
In total, 59 patients, 85% of which were female, met the inclusion criteria. The mean first episode of late growth was 4.3 (range 3-8.5) years. Head and neck location (55/59; 93%) and presence of deep hemangioma (52/59; 88%) were common characteristics. Posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects, eye abnormalities (PHACE) syndrome was noted in 20 of 38 (53%) children with segmental facial IH. Systemic therapy (corticosteroid or β-blocker) was given during infancy in 58 of 59 (98%) and 24 of 59 (41%) received systemic therapy (β-blockers) for late IH growth.
LIMITATIONS
CONCLUSIONS
The retrospective nature and ascertainment by investigator recall are limitations of the study.
CONCLUSION
CONCLUSIONS
Late IH growth can occur in children after 3 years of age. Risk factors include head and neck location, segmental morphology, and involvement of deep dermal/subcutaneous tissues.
Identifiants
pubmed: 30293898
pii: S0190-9622(18)32368-5
doi: 10.1016/j.jaad.2018.07.061
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Propranolol
9Y8NXQ24VQ
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-499Commentaires et corrections
Type : CommentIn
Informations de copyright
Crown Copyright © 2018. Published by Elsevier Inc. All rights reserved.